Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 64

1.

Preclinical evaluation of radiolabelled nimotuzumab, a promising monoclonal antibody targeting the epidermal growth factor receptor.

Barta P, Laznickova A, Laznicek M, Vera DR, Beran M.

J Labelled Comp Radiopharm. 2013 May 15;56(5):280-8. doi: 10.1002/jlcr.2988. Epub 2013 Jan 30.

PMID:
24285372
2.

Preparation and preclinical evaluation of 177Lu-nimotuzumab targeting epidermal growth factor receptor overexpressing tumors.

Vera DR, Eigner S, Henke KE, Lebeda O, Melichar F, Beran M.

Nucl Med Biol. 2012 Jan;39(1):3-13. doi: 10.1016/j.nucmedbio.2011.07.001. Epub 2011 Sep 29.

PMID:
21958849
3.

Preclinical evaluation of (177)lu-nimotuzumab: a potential tool for radioimmunotherapy of epidermal growth factor receptor-overexpressing tumors.

Vera DR, Eigner S, Beran M, Henke KE, Laznickova A, Laznicek M, Melichar F, Chinol M.

Cancer Biother Radiopharm. 2011 Jun;26(3):287-97. doi: 10.1089/cbr.2010.0916. Epub 2011 Jun 28.

PMID:
21711096
4.

¹¹¹In-Bn-DTPA-nimotuzumab with/without modification with nuclear translocation sequence (NLS) peptides: an Auger electron-emitting radioimmunotherapeutic agent for EGFR-positive and trastuzumab (Herceptin)-resistant breast cancer.

Fasih A, Fonge H, Cai Z, Leyton JV, Tikhomirov I, Done SJ, Reilly RM.

Breast Cancer Res Treat. 2012 Aug;135(1):189-200. doi: 10.1007/s10549-012-2137-y. Epub 2012 Jun 27.

PMID:
22736376
5.

A potencial theranostic agent for EGF-R expression tumors: (177)Lu-DOTA-nimotuzumab.

Calzada V, Zhang X, Fernandez M, Diaz-Miqueli A, Iznaga-Escobar N, Deutscher SL, Balter H, Quinn TP, Cabral P.

Curr Radiopharm. 2012 Oct;5(4):318-24.

PMID:
22280117
6.

Optimization of radioimmunotherapy of renal cell carcinoma: labeling of monoclonal antibody cG250 with 131I, 90Y, 177Lu, or 186Re.

Brouwers AH, van Eerd JE, Frielink C, Oosterwijk E, Oyen WJ, Corstens FH, Boerman OC.

J Nucl Med. 2004 Feb;45(2):327-37.

7.

[177Lu]Bz-DTPA-EGF: Preclinical characterization of a potential radionuclide targeting agent against glioma.

Sundberg AL, Gedda L, Orlova A, Bruskin A, Blomquist E, Carlsson J, Tolmachev V.

Cancer Biother Radiopharm. 2004 Apr;19(2):195-204.

PMID:
15186600
8.

(131)I-Nimotuzumab - A potential radioimmunotherapeutic agent in treatment of tumors expressing EGFR.

Kameswaran M, Samuel G, Dev Sarma H, Shinde SN, Dash A, Venkatesh M.

Appl Radiat Isot. 2015 Aug;102:98-102. doi: 10.1016/j.apradiso.2015.05.001. Epub 2015 May 6.

PMID:
26002276
9.

Comparative in vitro and experimental in vivo studies of the anti-epidermal growth factor receptor antibody nimotuzumab and its aglycosylated form produced in transgenic tobacco plants.

Rodríguez M, Pérez L, Gavilondo JV, Garrido G, Bequet-Romero M, Hernández I, Huerta V, Cabrera G, Pérez M, Ramos O, Leyva R, León M, Ramos PL, Triguero A, Hernández A, Sánchez B, Ayala M, Soto J, González E, Mendoza O, Tiel K, Pujol M.

Plant Biotechnol J. 2013 Jan;11(1):53-65. doi: 10.1111/pbi.12006. Epub 2012 Oct 10.

10.

[(177)Lu]pertuzumab: experimental studies on targeting of HER-2 positive tumour cells.

Persson M, Tolmachev V, Andersson K, Gedda L, Sandström M, Carlsson J.

Eur J Nucl Med Mol Imaging. 2005 Dec;32(12):1457-62. Epub 2005 Sep 29.

PMID:
16193312
11.

Biodistribution and internal dosimetry of the 188Re-labelled humanized monoclonal antibody anti-epidemal growth factor receptor, nimotuzumab, in the locoregional treatment of malignant gliomas.

Torres LA, Coca MA, Batista JF, Casaco A, Lopez G, García I, Perera A, Peña Y, Hernández A, Sanchez Y, Romero S, Leyva R, Prats A, Fernandez R.

Nucl Med Commun. 2008 Jan;29(1):66-75.

PMID:
18049099
12.

(177)Lu/ (90)Y intermediate-affinity monoclonal antibodies targeting EGFR and HER2/c-neu: preparation and preclinical evaluation.

Beckford Vera DR, Eigner S, Eigner Henke K, Leyva Montaña R, Melichar F, Beran M.

Recent Results Cancer Res. 2013;194:301-17. doi: 10.1007/978-3-642-27994-2_16.

PMID:
22918766
13.

Synthesis of 99mTc-nimotuzumab with tricarbonyl ion: in vitro and in vivo studies.

Garcia MF, Camacho X, Calzada V, Fernandez M, Porcal W, Alonso O, Gambini JP, Cabral P.

Curr Radiopharm. 2012 Jan;5(1):59-64.

PMID:
22074480
14.

Preclinical evaluation of 227Th-labeled and 177Lu-labeled trastuzumab in mice with HER-2-positive ovarian cancer xenografts.

Abbas N, Bruland ØS, Brevik EM, Dahle J.

Nucl Med Commun. 2012 Aug;33(8):838-47. doi: 10.1097/MNM.0b013e328354df7c.

PMID:
22643311
15.

Nimotuzumab promotes radiosensitivity of EGFR-overexpression esophageal squamous cell carcinoma cells by upregulating IGFBP-3.

Zhao L, He LR, Xi M, Cai MY, Shen JX, Li QQ, Liao YJ, Qian D, Feng ZZ, Zeng YX, Xie D, Liu MZ.

J Transl Med. 2012 Dec 11;10:249. doi: 10.1186/1479-5876-10-249.

16.

Bivalent binding by intermediate affinity of nimotuzumab: a contribution to explain antibody clinical profile.

Garrido G, Tikhomirov IA, Rabasa A, Yang E, Gracia E, Iznaga N, Fernández LE, Crombet T, Kerbel RS, Pérez R.

Cancer Biol Ther. 2011 Feb 15;11(4):373-82. Epub 2011 Feb 15.

PMID:
21150278
17.

The effect of chelator type on in vitro receptor binding and stability in 177Lu-labeled cetuximab and panitumumab.

Novy Z, Laznickova A, Mandikova J, Barta P, Laznicek M, Trejtnar F.

J Labelled Comp Radiopharm. 2014 Jun 15;57(7):448-52. doi: 10.1002/jlcr.3204. Epub 2014 May 29.

PMID:
24889367
18.

Enhancement of the antitumor activity of ionising radiation by nimotuzumab, a humanised monoclonal antibody to the epidermal growth factor receptor, in non-small cell lung cancer cell lines of differing epidermal growth factor receptor status.

Akashi Y, Okamoto I, Iwasa T, Yoshida T, Suzuki M, Hatashita E, Yamada Y, Satoh T, Fukuoka M, Ono K, Nakagawa K.

Br J Cancer. 2008 Feb 26;98(4):749-55. doi: 10.1038/sj.bjc.6604222. Epub 2008 Feb 5.

19.

Development of a radioiodinated apoptosis-inducing ligand, rhTRAIL, and a radiolabelled agonist TRAIL receptor antibody for clinical imaging studies.

Duiker EW, Dijkers EC, Lambers Heerspink H, de Jong S, van der Zee AG, Jager PL, Kosterink JG, de Vries EG, Lub-de Hooge MN.

Br J Pharmacol. 2012 Apr;165(7):2203-12. doi: 10.1111/j.1476-5381.2011.01718.x.

20.

Preparation and preliminary biological evaluation of 177Lu-labelled hydroxyapatite as a promising agent for radiation synovectomy of small joints.

Chakraborty S, Das T, Banerjee S, Sarma HD, Venkatesh M.

Nucl Med Commun. 2006 Aug;27(8):661-8.

PMID:
16829766

Supplemental Content

Support Center